Biocause Pharma(000627)2024-04-15 10:04Financial Performance Expectations - The company expects a net profit loss of between 80 million and 110 million yuan for Q1 2024, compared to a profit of 45.21 million yuan in the same period last year[2]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of between 88 million and 118 million yuan, compared to a profit of 43.72 million yuan last year[2]. - The basic earnings per share are projected to be a loss of between 0.016 yuan and 0.022 yuan, compared to earnings of 0.01 yuan per share in the previous year[2]. Subsidiary Performance - The company’s subsidiary, Guohua Life, reported original insurance premium income of 15.206 billion yuan in Q1 2024, indicating a stable overall scale[5]. - Guohua Life aims to maintain a stable premium income while adjusting business pace and structure according to market conditions, focusing on long-term value and risk protection business development[4]. Factors Affecting Performance - The decline in performance is attributed to the downward trend in the 750-day moving average of the national bond yield curve, leading to increased reserve provisions by Guohua Life and reduced investment income[4]. Business Strategy and Outlook - The company plans to continue optimizing its business structure and asset allocation, enhancing operational capabilities through new technology applications and talent reserves[4]. - The financial department's preliminary calculations form the basis of this earnings forecast, with detailed disclosures to follow in the Q1 2024 report[6]. - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the earnings forecast[6]. Announcement Details - The announcement was made by the board of directors on April 15, 2024[7].